Abatacept (Orencia®)

Assessment Status NCPE Assessment Process Complete
Drug Abatacept
Brand Orencia®
Indication In combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.
Assessment Process
Rapid review commissioned 28/11/2012
Rapid review completed 21/12/2012
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full submission received from Applicant 02/07/2013
NCPE assessment completed 11/11/2013
NCPE assessment outcome Reimbursement not recommended at the submitted price

Technical Summary

November 2015

The HSE has approved reimbursement following confidential pricing negotiations.